Your session is about to expire
← Back to Search
Antiplatelet agent
Clopidogrel - for CYP2C19*2 carriers for Heart Attack (ELEVATE Trial)
Phase 2
Waitlist Available
Led By Christian T Ruff, MD, MPH
Research Sponsored by The TIMI Study Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately every 2 weeks for 8 weeks
Awards & highlights
Summary
To determine whether higher as compared with lower maintenance doses of clopidogrel can adequately improve the degree of platelet inhibition in carriers of a reduced-function CYP2C19 allele.
Eligible Conditions
- Heart Attack
- Percutaneous Coronary Intervention
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately every 2 weeks for 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately every 2 weeks for 8 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI)
Trial Design
2Treatment groups
Active Control
Group I: Clopidogrel - for CYP2C19*2 carriersActive Control1 Intervention
Clopidogrel for CYP2C19\*2 gene carriers
Group II: Clopidogrel - for CYP2C19*2 non-carriersActive Control1 Intervention
Clopidogrel for CYP2C19\*2 gene NON-carriers
Find a Location
Who is running the clinical trial?
The TIMI Study GroupLead Sponsor
12 Previous Clinical Trials
83,100 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,678 Previous Clinical Trials
4,125,310 Total Patients Enrolled
SanofiIndustry Sponsor
2,187 Previous Clinical Trials
3,979,443 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger